Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma

Gynecol Oncol. 2017 Jul;146(1):11-15. doi: 10.1016/j.ygyno.2017.03.508. Epub 2017 Apr 6.
No abstract available

Keywords: Maintenance; Ovarian cancer; PARP inhibitor; Treatment.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Disease-Free Survival
  • Female
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / enzymology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors